Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





BIOTYPE Introduces Diagnostics and Cancer Profiling Assays at MEDICA 2026

By LabMedica International staff writers
Posted on 16 Nov 2026

BIOTYPE (Dresden, Germany) presents its molecular diagnostic assays and testing technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. More...

The company highlights new solutions for molecular oncology, pharmacogenetics, and automated sample preparation, alongside its broader portfolio of in vitro diagnostic (IVD) assays and development services for clinical laboratories and diagnostic manufacturers.

Among the products on display is the new Mentype AMLplus Mutation Analysis Kit, a multiplex PCR assay for detecting genetic mutations associated with acute myeloid leukemia (AML). The assay simultaneously analyzes mutation hotspots in IDH1, IDH2, FLT3, NPM1, and CEBPA using blood or bone marrow samples. It provides results in approximately four hours after nucleic acid extraction and includes software for standardized data interpretation.

BIOTYPE also presents the new ExaccType ESR1 dPCR Kit, designed to detect 11 ESR1 mutations across exons 5, 7, and 8 using digital PCR. The research-use-only assay demonstrated detection at mutant allele frequencies as low as 0.1% under evaluated conditions. It supports the analysis of DNA, including plasma-derived cell-free DNA, for research into breast cancer progression, endocrine resistance, and liquid biopsy biomarkers.

Another addition is the ExaccType DPYD Kit, a multiplex quantitative PCR (qPCR) assay for detecting seven predefined DPYD variants associated with fluoropyrimidine metabolism. The research-use-only test analyzes purified genomic DNA or whole blood and uses four multiplex reactions per sample. It is designed to support pharmacogenetic research and investigations into genetic factors affecting drug metabolism.

The exhibition also features BIOTYPE's portfolio of molecular diagnostic assays supporting hemato-oncology, chimerism monitoring, solid tumor profiling, and liquid biopsy applications. The company presents its IVDR-compliant testing solutions alongside research assays, highlighting approaches to identifying molecular alterations relevant to cancer diagnosis, disease monitoring, and precision medicine.

In addition to molecular assays, BIOTYPE showcases automated sample preparation technologies designed to streamline laboratory workflows. These solutions support sample processing and preparation for downstream molecular analysis, with applications in oncology and other diagnostic fields. Automation is intended to improve workflow standardization and reduce manual handling during laboratory testing.

BIOTYPE also highlights its contract development and manufacturing services for molecular diagnostics. The company provides assay development, optimization, and manufacturing support to diagnostic and biotechnology companies, covering different stages of product development. These services complement its existing molecular testing portfolio and support the development of new diagnostic technologies.

BIOTYPE exhibits at Booth 3C72-2 in Hall 3, where visitors can explore its molecular diagnostic technologies and discuss potential research and commercial collaborations. The company is using its participation at MEDICA 2026 to connect with laboratory professionals, distributors, and diagnostic manufacturers as it expands its molecular diagnostics activities.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.